Management of IgA nephropathy: contemporary views
|
|
- Griffin Lambert
- 5 years ago
- Views:
Transcription
1 Management of IgA nephropathy: contemporary views MBBS, MD, PhD, MRCP (UK), FHKCP, FHKAM (Medicine) Associate Consultant and Honorary Associate Professor, Department of Medicine, University of Hong Kong, Queen Mary Hospital Prof. Kar-neng Lai MD, DSc, FRCPath, FRCP (Lond, Edin & Glas), FRACP, FACP, FAMS, FHKCP, FHKAM (Medicine) Head and Chief of Service, Department of Medicine, University of Hong Kong, Queen Mary Hospital Prof. Kar-neng Lai This article has been selected by the Editorial Board of the Hong Kong Medical Diary for participants in the CME programme of the Medical Council of Hong Kong (MCHK) to complete the following self-assessment questions in order to be awarded one CME credit under the programme upon returning the completed answer sheet to the Federation Secretariat on or before 31 May Ever since its first description in 1968 by the French pathologist, J. Berger 1, IgA nephropathy (IgAN) has remained the commonest primary glomerulonephritis worldwide 2. In Hong Kong, the commonest renal manifestation is microscopic haematuria which is often synpharyngitic 3. The disease is unique among g l o m e r u l o p a t h i e s i n b e i n g d e f i n e d b y immunohistochemical findings of mesangial deposition of IgA (Figure 1), rather than by light microscopy in which mesangial cell proliferation is the commonest feature (Figure 2). Another hallmark of the disease is its indolent progressive nature. Between 15% and 40% of adults and children will eventually progress to end stage renal disease 4;5. Approximately 15 to 20% develop ESRD within 10 years, and 30 to 35% develop ESRD within 20 years of onset. Proteinuria, elevated serum creatinine, and hypertension predict progression 6, as does renal biopsy demonstrating focal proliferative glomerulonephritis with crescents, diffuse proliferative glomerulonephritis, or advanced, chronic lesions of tubulointerstitial fibrosis 7. Until recently, there was no effective treatment available for patients with IgAN. Although there remains no cure, treatment options that slow disease progression are becoming available. In this update I will review the current armamentarium in the management of IgAN. Conservative treatment For patients with normal renal function, normotension and only minor urinary abnormalities, such as isolated microhaematuria, and/or low grade proteinuria, the general consensus is not to offer specific treatment but to keep such patients under review. Up to 23% of patients will have a spontaneous complete remission. Blockers of the renin-angiotensin system Reduction in proteinuria is considered to be the hallmark of effective treatment in preserving renal function in nondiabetic renal diseases. Angiotensinconverting enzyme inhibitors (ACEi), and more recently angiotensin II type 1 receptor blockers (ARB), are widely used to control blood pressure and proteinuria, both of which are considered modifiable risk factors for progressive disease, in IgAN subjects with significant proteinuria with or without hypertension. They are superior to other antihypertensives in lowering proteinuria by virtue of their capacity to reduce intraglomerular pressure. Response to ACEi in IgAN has been reported to be related to the ACE genotype, with more favourable outcome in subjects with the DD genotype over those with ID or II genotypes 8. Limited data are available on the effects on proteinuria of combination therapy with ACEi/ARB. In a small trial, the combination of losartan and enalapril appeared to have an additive effect on the reduction of urinary protein excretion, whereas doubling the dose of monotherapy had no effect 9. In the COOPERATE study 10 in which half of the subjects had IgAN, combination treatment safely retarded progression of non-diabetic renal disease compared with monotherapy. One of the precautions in prescribing monotherapy or dual therapy is refractory hyperkalaemia particularly in subjects with significant renal impairment. Another precaution is the precipitation of acute renal failure in subjects with bilateral renovascular disease. Corticosteroids Corticosteroids have been used for over 20 years in the treatment of IgAN because of their antiinflammatory and immunosuppressive properties, and are usually confined to patients considered at risk of progressive renal failure. A meta-analysis of six available trials of sufficient quality suggested that corticosteroid therapy may be effective in reducing proteinuria, although the impact on protecting renal function is less clear 11. In an RCT from Italy, treatment with steroids (1 g/d of intravenous methylprednisolone for 3 d at the beginning of months 1, 3, and 5, plus 0.5 mg of oral prednisone/kg BW on alternate days for 6 m) was shown to lower proteinuria by 50% after 6 months and to reduce the risk of a 50% increase in the serum creatinine level by 36% after five years 12. The long-term follow-up data from this study showed impressive benefits of corticosteroid treatment in reducing proteinuria and preventing ESRD 13. Although several 3
2 other studies have shown beneficial results in small numbers of patients treated with daily or alternate-day steroid early in their illness, long-term efficacy in controlling disease progression has not been validated in Chinese patients, and therapy is only beneficial to selected groups of patients with IgAN and nephrotic syndrome 14. Another recent RCT of corticosteroids showed only a modest reduction in proteinuria with no protection of GFR amongst Japanese patients 15. At this juncture, steroid does not appear to consistently offer any beneficial effect other than modest amelioration of proteinuria. The only exception is found in children with IgA deposition in the setting of minimal change nephrotic syndrome. Such patients respond to corticosteroid promptly 16. In adults, in view of the toxicities associated with steroid therapy, it should be considered only when proteinuria persists >1 g/24 h despite optimal BP control and maximum RAS blockade. Fish oil (n-3 Polyunsaturated Fatty Acids) supplementation The first landmark report on the efficacy of dietary fish-oil supplements was published in 1994 from the Mayo Clinic 17. The rationale of using fish oil in IgAN is based on the premise that ω-3 polyunsaturated fatty acids alter the production or action of cytokines and eicosanoids evoked by the initial or by repeated immunological renal injury, thereby alleviating ongoing renal inflammation and glomerulosclerosis, both being hallmarks of progressive renal disease. However, a meta-analysis of 5 controlled trials failed to substantiate the efficacy of fish oil in IgAN 18. The mean effect to indicate that treatment was superior to control was not statistically significant. Despite this, the Mayo investigators published their long-term data in 1999 to conclude that early and prolonged treatment with fish oil slows renal progression for high-risk patients with IgAN 19. Locally, a study performed in the late 1980s on 11 patients with IgAN given dietary fish oil supplement showed either no demonstrable or an unpredictable effect 20. The preliminary report of a more recent RCT showed no benefit of 2 years of treatment with fish oil compared with corticosteroids and placebo 21. Hence, the clinical benefit of fish oil supplementation in IgAN cannot be established at this point, and primary treatment of IgAN with fish oil is not recommended. Cyclophosphamide Only one study suggested efficacy of cyclophosphamide followed by azathioprine in conjunction with high-dose prednisolone in patients who are at very high risk for progression (ESRD predicted in all cases within 5 yr) 22. However, these are only a small minority of patients encountered in clinical practice. Thus, there is insufficient evidence to justify the use of such cytotoxic agent in IgAN except in crescentic IgAN with rapidly progressive renal failure. Mycophenolate mofetil (MMF) The rationale for employing MMF to treat IgAN stems from its selective suppressive effects on lymphocyte proliferation and antibody formation 23. Four clinical trials have been published so far which together gave no conclusion. We provided evidence that a 6-month course of MMF (0.75 to 1 g b.d.) can induce lasting remission (up to 72 weeks of follow up thus far) of proteinuria in at-risk patients (i.e. those with persistent proteinuria >1g/day despite full RAS inhibition and normal BP, but had histology that did not reveal advanced sclerosis) 24. Similarly, another report from Beijing suggested that MMF is more effective than prednisone in reducing proteinuria in patients with urine protein > 2 g/d 25. Conversely, lack of efficacy was reported from Belgium (MMF for 3 years in 21 patients with histologic unfavourable criteria, arterial hypertension, and inulin clearance between 21 and 69 ml/min) 26 and North America (MMF for 1 year as a "salvage" therapy in 16 patients with advanced renal insufficiency) 27. Such discrepancies likely arise from a difference in race, and our selection of patients with less advanced disease. It would be reasonable at this point to recommend MMF to at-risk patients without advanced sclerosis who can afford this expensive drug. Kidney transplantation Kidney transplantation offers the best potential for full rehabilitation in ESRD from IgAN. Disease recurrence in the allograft typically is slowly progressive. Available evidence indicates at 5 years a 5% risk for graft failure due to recurrence, a 13% risk for significant graft dysfunction, and at least 50% risk for IgA deposition. Local data suggest that around 20% of patients developed recurrence by 5 years after transplantation 28. The risk for graft loss increases markedly to 25% when a first graft was lost to recurrence. There is no consistent evidence that these risks differ between living and cadaveric donors 29. Into the future Short of an effective cure of IgAN, future therapeutic attempts should target the prevention of mesangial IgA deposition and the amelioration of the ensuing downstream inflammatory injury induced by infiltrating neutrophils and the released cytokines 30. Based on pathogenetic insights derived from experimental studies, antagonism of platelet-derived growth factor and transforming growth factor provides an attractive and possibly more specific therapeutic alternative to immunosuppression. At present, the development of other novel therapeutic approaches is greatly hampered by the lack of animal models that resemble human IgAN. 4
3 Figure 1 Predominant or co-dominant deposition of IgA in the mesangium is the defining hallmark in IgAN. IgG, IgM, and C3 deposition may also accompany IgA. Magnification x 200 Figure 2 Classical mesangial cell proliferation in IgAN. PAS staining, magnification x 200 References 1. Berger J, Hinglais N: [Intercapillary deposits of IgA-IgG]. J Urol Nephrol (Paris) 74: , D'Amico G: The commonest glomerulonephritis in the world: IgA nephropathy. Q J Med 64: , Lai KN, Mac-Moune LF, Li PK, Chan KW, Au TC, Tong KL: The clinicopathological characteristics of IgA nephropathy in Hong Kong. Pathology 20:15-19, Tang S, Lai KN: IgA nephropathy: 30 years on. Medical Progress 26:814, Wyatt RJ, Kritchevsky SB, Woodford SY, Miller PM, Roy S, III, Holland NH, Jackson E, Bishof NA: IgA nephropathy: long-term prognosis for pediatric patients. J Pediatr 127: , D'Amico G: Natural history of idiopathic IgA nephropathy: role of clinical and histological prognostic factors. Am J Kidney Dis 36:227237, Coppo R, D'Amico G: Factors predicting progression of IgA nephropathies. J Nephrol 18: , Tang S, Lai KN: Gene polymorphism in IgA nephropathy. Nephrology 6:63-70, Russo D, Minutolo R, Pisani A, Esposito R, Signoriello G, Andreucci M, Balletta MM: Coadministration of losartan and enalapril exerts additive antiproteinuric effect in IgA nephropathy. Am J Kidney Dis 38:18-25, Nakao N, Yoshimura A, Morita H, Takada M, Kayano T, Ideura T: Combination treatment of angiotensin-ii receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 361: , Samuels JA, Strippoli GF, Craig JC, Schena FP, Molony DA: Immunosuppressive treatments for immunoglobulin A nephropathy: a meta-analysis of randomized controlled trials. Nephrology 9: , Pozzi C, Bolasco PG, Fogazzi GB, Andrulli S, Altieri P, Ponticelli C, Locatelli F: Corticosteroids in IgA nephropathy: a randomised controlled trial. Lancet 353: , Pozzi C, Andrulli S, Del Vecchio L, Melis P, Fogazzi GB, Altieri P, Ponticelli C, Locatelli F: Corticosteroid effectiveness in IgA nephropathy: long-term results of a randomized, controlled trial. J Am Soc Nephrol 15: , Lai KN, Lai FM, Ho CP, Chan KW: Corticosteroid therapy in IgA nephropathy with nephrotic syndrome: a long-term controlled trial. Clin Nephrol 26: , Katafuchi R, Ikeda K, Mizumasa T, Tanaka H, Ando T, Yanase T, Masutani K, Kubo M, Fujimi S: Controlled, prospective trial of steroid treatment in IgA nephropathy: a limitation of low-dose prednisolone therapy. Am J Kidney Dis 41: , Lai KN, Lai FM, Chan KW, Ho CP, Leung AC, Vallance-Owen J: An overlapping syndrome of IgA nephropathy and lipoid nephrosis. Am J Clin Pathol 86: , Donadio JV, Bergstralh EJ, Offord KP, Spencer DC, Holley KE, The Mayo Nephrology Collaborative Group: A Controlled Trial of Fish Oil in IgA Nephropathy. N Engl J Med 331: , Dillon JJ: Fish oil therapy for IgA nephropathy: efficacy and interstudy variability. J Am Soc Nephrol 8: , Donadio JV, Jr., Grande JP, Bergstralh EJ, Dart RA, Larson TS, Spencer DC: The long-term outcome of patients with IgA nephropathy treated with fish oil in a controlled trial. Mayo Nephrology Collaborative Group. J Am Soc Nephrol 10: , Cheng IK, Chan PC, Chan MK: The effect of fish-oil dietary supplement on the progression of mesangial IgA glomerulonephritis. Nephrol Dial Transplant 5: , Hogg, R. J., Lee, J., Narelli, N., Cattran, D. C., Hirschman, G., and Julian, B. A. Multicenter placebo-controlled trial of alternate day prednisolone or daily omega-3 fatty acids in children and young adults with IgA nephropathy. Report from the Southwest Pediatric Nephrology Study Group. Journal of the American Society of Nephrology 14, 751A Ballardie FW, Roberts IS: Controlled prospective trial of prednisolone and cytotoxics in progressive IgA nephropathy. J Am Soc Nephrol 13: , Allison AC, Eugui EM: Purine metabolism and immunosuppressive effects of mycophenolate mofetil (MMF). Clin Transplant 10:77-84, Tang S, Leung JC, Chan LY, Lui YH, Tang CS, Kan CH, Ho YW, Lai KN: Mycophenolate mofetil alleviates persistent proteinuria in IgA nephropathy. Kidney Int 68: , Chen X, Chen P, Cai G, Wu J, Cui Y, Zhang Y, Liu S, Tang L: [A randomized control trial of mycophenolate mofeil treatment in severe IgA nephropathy]. Zhonghua Yi Xue Za Zhi 82: , Maes BD, Oyen R, Claes K, Evenepoel P, Kuypers D, Vanwalleghem J, Damme BV, Vanrenterghem YF: Mycophenolate mofetil in IgA nephropathy: Results of a 3-year prospective placebo-controlled randomized study. Kidney Int 65: , Frisch G, Lin J, Rosenstock J, Markowitz G, D'Agati V, Radhakrishnan J, Preddie D, Crew J, Valeri A, Appel G: Mycophenolate mofetil (MMF) vs placebo in patients with moderately advanced IgA nephropathy: a double-blind randomized controlled trial. Nephrol Dial Transplant 20: , Choy BY, Chan TM, Lo SK, Lo WK, Lai KN: Renal transplantation in patients with primary immunoglobulin A nephropathy. Nephrol Dial Transplant 18: , Floege J: Recurrent IgA nephropathy after renal transplantation. Semin Nephrol 24: , Lai KN: Future directions in the treatment of IgA nephropathy. Nephron 92: ,
4 MCHK CME Programme Self-assessment Questions Please read the article entitled "Management of IgA nephropathy: contemporary views" by and complete the following self-assessment questions. Participants in the MCHK CME Programme will be awarded 1 CME credit under the Programme for returning completed answer sheet via fax ( ) or by mail to the Federation Secretariat on or before 31 May Answers to questions will be provided in the next issue of The Hong Kong Medical Diary. Questions 1-10: Please choose the best answer. 1. What investigation is needed to make a definitive diagnosis of IgAN? a. Serum IgA level b. Urine RBC c. Renal biopsy d. 24-hour Urine protein 2. What is the confirmatory histologic feature in IgAN? a. Mesangial proliferation b. Concomitant IgA deposition c. Double contouring of glomerular basement membrane d. Predominant or codominant mesangial IgA deposit 3. What is the commonest mode of presentation? a. Microscopic haematuria (often incidentally found) b. Hypertension c. Nephrotic syndrome d. Gross haematuria 4. Which is not a modifiable risk factor for progression to ESRD in IgAN a. Proteinuria b. Haematuria c. Hypertension 5. Which is the drug of first choice for patients with significant proteinuria regardless of blood pressure? a. Ca channel blocker b. MMF c. ACEi and/or ARB d. Corticosteroid 6. Which of the following is not a potential adverse effect of RAS blockade a. Hyponatraemia b. Hyperkalaemia in patients with CRF c. Acute renal failure in subjects with bilateral renal artery stenoses d. Dry cough 7. Is corticosteroid a standard form of treatment for IgAN? a. No b. Yes 8. When should corticosteroid be considered in IgAN? a. In gross haematuria b. In proteinuria c. In microscopic haematuria d. In crescentic IgAN 9. When should mycophenolate be considered in IgAN? a. Advanced renal insufficiency b. Refractory proteinuria despite full RAS blockade in the absence of significant kidney fibrosis c. Before renal transplantation d. Recurrent synpharyngitic haematuria 10. What may be a peculiar feature in patients who undergo renal transplantation due to ESRD resulting from IgAN? a. Acute allograft rejection b. Recurrent IgAN c. Graft thrombosis d. Polycythaemia 6
5 ANSWER SHEET FOR MAY 2006 Please return the completed answer sheet to the Federation Secretariat on or before 31 May 2006 for documentation. 1 CME point will be awarded for answering the MCHK CME programme (for non-specialists) self-assessment questions. Management of IgA nephropathy: contemporary views MBBS, MD, PhD, MRCP (UK), FHKCP, FHKAM (Medicine) Associate Consultant and Honorary Associate Professor, Department of Medicine, University of Hong Kong, Queen Mary Hospital Name: HKID No. - X X (x) Signature: Contact Tel No.: Answers to April 2006 issue Management of First Epileptic Seizure 1. D 2. E 3. C 4. D 5. B 6. E 7. D 8. E 9. D 10. E CALL FOR SUBMISSION OF ARTICLES FOR PUBLICATION IN THE HONG KONG MEDICAL DIARY The Editorial Board of the Hong Kong Medical Diary invites you to send in your interesting articles for publication in the Hong Kong Medical Diary (500-1,500 words per article). Abstracts from recent local or international meetings/symposia are also welcome. You can send in your manuscript by facsimile at , through mail or via at sue.cheng@fmshk.com.hk. The Editorial Board of the Hong Kong Medical Diary will give you a prompt reply. 7
The CARI Guidelines Caring for Australasians with Renal Impairment. Specific management of IgA nephropathy: role of steroid therapy GUIDELINES
Specific management of IgA nephropathy: role of steroid therapy Date written: July 2005 Final submission: September 2005 Author: Merlin Thomas GUIDELINES Steroid therapy may protect against progressive
More informationThe CARI Guidelines Caring for Australasians with Renal Impairment. Specific management of IgA nephropathy: role of fish oil
Specific management of IgA nephropathy: role of fish oil Date written: July 2005 Final submission: September 2005 Author: Merlin Thomas GUIDELINES Early and prolonged treatment with fish oil may retard
More informationReducing proteinuria
Date written: May 2005 Final submission: October 2005 Author: Adrian Gillin Reducing proteinuria GUIDELINES a. The beneficial effect of treatment regimens that include angiotensinconverting enzyme inhibitors
More informationIgA Nephropathy - «Maladie de Berger»
IgA Nephropathy - «Maladie de Berger» B. Vogt, Division de Néphrologie/Consultation d Hypertension CHUV, Lausanne 2011 Montreux CME SGN-SSN IgA Nephropathy 1. Introduction 2. Etiology and Pathogenesis
More informationEVIDENCE BASED TREATMENT OF IgA NEPHROPATHY. Jonathan Barratt
EVIDENCE BASED TREATMENT OF IgA NEPHROPATHY Jonathan Barratt EVIDENCE BASED TREATMENT OF IgA NEPHROPATHY We do not have much evidence EVIDENCE BASED TREATMENT OF IgA NEPHROPATHY We do not have much evidence.
More informationCurrent treatment recommendations in children with IgA nephropathy Selçuk Yüksel
Current treatment recommendations in children with IgA nephropathy Selçuk Yüksel Department of Pediatric Nephrology Pamukkale University School of Medicine IgA Nephropathy The most common cause of primary
More informationThe CARI Guidelines Caring for Australasians with Renal Impairment
Specific management of IgA nephropathy: role of triple therapy and cytotoxic therapy Date written: July 2005 Final submission: September 2005 Author: Merlin Thomas GUIDELINES a. Triple therapy with cyclophosphamide,
More informationCase Report Corticosteroids in Patients with IgA Nephropathy and Severe Chronic Renal Damage
Case Reports in Nephrology Volume, Article ID 89, pages doi:.//89 Case Report Corticosteroids in Patients with IgA Nephropathy and Severe Chronic Renal Damage Claudio Pozzi, Francesca Ferrario, Bianca
More informationof IgA nephropathy: a systematic review
Original Article Singapore Med12008,49(10):780 Mycophenolate mofetil in the treatment of IgA nephropathy: a systematic review Tan C H R, Loh P T, Yang W S, Chan C M ABSTRACT Introduction: The aim of this
More informationThe CARI Guidelines Caring for Australasians with Renal Impairment. Idiopathic membranous nephropathy: use of other therapies GUIDELINES
Idiopathic membranous nephropathy: use of other therapies Date written: July 2005 Final submission: September 2005 Author: Merlin Thomas GUIDELINES No recommendations possible based on Level I or II evidence
More informationIgA-Nephropathy: an update on treatment Jürgen Floege
IgA-Nephropathy: an update on treatment Jürgen Floege Division of Nephrology & Immunology juergen.floege@rwth-aachen.de Floege & Feehally, Nat Rev Nephrol 2013 Floege & Eitner, J Am Soc Nephrol. 2011 If
More informationClinical and pathological characteristics of patients with glomerular diseases at a university teaching hospital: 5-year prospective review
Clinical and pathological characteristics of patients with glomerular diseases at a university teaching hospital: 5-year prospective review KW Chan, TM Chan, IKP Cheng Objective. To examine the prevalence
More informationNDT Advance Access published August 6, 2008
NDT Advance Access published August 6, 2008 Nephrol Dial Transplant (2008) 1 5 doi: 10.1093/ndt/gfn454 Original Article Combined treatment with renin angiotensin system blockers and polyunsaturated fatty
More informationThe CARI Guidelines Caring for Australasians with Renal Impairment. Membranous nephropathy role of steroids GUIDELINES
Membranous nephropathy role of steroids Date written: July 2005 Final submission: September 2005 Author: Merlin Thomas GUIDELINES There is currently no data to support the use of short-term courses of
More informationClinicopathologic Characteristics of IgA Nephropathy with Steroid-responsive Nephrotic Syndrome
J Korean Med Sci 2009; 24 (Suppl 1): S44-9 ISSN 1011-8934 DOI: 10.3346/jkms.2009.24.S1.S44 Copyright The Korean Academy of Medical Sciences Clinicopathologic Characteristics of IgA Nephropathy with Steroid-responsive
More informationNephrotic syndrome minimal change disease vs. IgA nephropathy. Hadar Meringer Internal medicine B Sheba
Nephrotic syndrome minimal change disease vs. IgA nephropathy Hadar Meringer Internal medicine B Sheba The Case 29 year old man diagnosed with nephrotic syndrome 2 weeks ago and complaining now about Lt.flank
More informationThe CARI Guidelines Caring for Australasians with Renal Impairment. Blood Pressure Control role of specific antihypertensives
Blood Pressure Control role of specific antihypertensives Date written: May 2005 Final submission: October 2005 Author: Adrian Gillian GUIDELINES a. Regimens that include angiotensin-converting enzyme
More informationUse of mycophenolate mofetil in steroid-dependent and -resistant nephrotic syndrome
Pediatr Nephrol (2003) 18:833 837 DOI 10.1007/s00467-003-1175-4 BRIEF REPORT Gina-Marie Barletta William E. Smoyer Timothy E. Bunchman Joseph T. Flynn David B. Kershaw Use of mycophenolate mofetil in steroid-dependent
More informationC1q nephropathy the Diverse Disease
C1q nephropathy the Diverse Disease Danica Galešić Ljubanović School of Medicine, University of Zagreb Dubrava University Hospital Zagreb, Croatia Definition Dominant or codominant ( 2+), mesangial staining
More informationIdiopathic minimal change nephrotic syndrome in older adults: steroid responsiveness and pattern of relapses
Nephrol Dial Transplant (2003) 18: 1316 1320 DOI: 10.1093/ndt/gfg134 Original Article Idiopathic minimal change nephrotic syndrome in older adults: steroid responsiveness and pattern of relapses Kai-Chung
More informationChapter 4: Steroid-resistant nephrotic syndrome in children Kidney International Supplements (2012) 2, ; doi: /kisup.2012.
http://www.kidney-international.org & 2012 KDIGO Chapter 4: Steroid-resistant nephrotic syndrome in children Kidney International Supplements (2012) 2, 172 176; doi:10.1038/kisup.2012.17 INTRODUCTION This
More informationNephrology Grand Rounds. Mansi Mehta November 24, 2015
Nephrology Grand Rounds Mansi Mehta November 24, 2015 Case 51yo F with PMH significant for Hypertension referred to renal clinic for evaluation of elevated Cr. no known history of CKD; baseline creatinine
More informationThe improvement of renal survival with steroid pulse therapy in IgA nephropathy
Nephrol Dial Transplant (2008) 23: 3915 3920 doi: 10.1093/ndt/gfn394 Advance Access publication 20 July 2008 Original Article The improvement of renal survival with steroid pulse therapy in IgA nephropathy
More informationCHAPTER 2 PRIMARY GLOMERULONEPHRITIS
CHAPTER 2 Sunita Bavanandan Lim Soo Kun 19 5th Report of the 2.1: Introduction This chapter covers the main primary glomerulonephritis that were reported to the MRRB from the years 2005-2012. Minimal change
More informationThe CARI Guidelines Caring for Australians with Renal Impairment. Membranous nephropathy Role of alkylating agents GUIDELINES
Membranous nephropathy Role of alkylating agents Date written: July 2005 Final submission: September 2005 Author: Merlin Thomas GUIDELINES a. Treatment with alkylating agents is associated with an increased
More informationOverview of Treatment of IgA Nephropathy
BANTAO Journal 2010; 8 (1): 1-8 BJ BANTAO Journal Review article Overview of Treatment of IgA Nephropathy Pantelitsa C. Kalliakmani, Miltiadis Gerolymos and Dimitrios S. Goumenos Department of Internal
More informationCHAPTER 2. Primary Glomerulonephritis
2nd Report of the PRIMARY GLOMERULONEPHRITIS CHAPTER 2 Primary Glomerulonephritis Sunita Bavanandan Lee Han Wei Lim Soo Kun 21 PRIMARY GLOMERULONEPHRITIS 2nd Report of the 2.1 Introduction This chapter
More informationRecurrent Idiopathic Membranous Glomerulonephritis After Kidney Transplantation and Successful Treatment With Rituximab
TRANSPLANTATION Recurrent Idiopathic Membranous Glomerulonephritis After Kidney Transplantation and Successful Treatment With Rituximab Khadijeh Makhdoomi, 1,2 Saeed Abkhiz, 1,2 Farahnaz Noroozinia, 1,3
More informationThe CARI Guidelines Caring for Australasians with Renal Impairment. ACE Inhibitor and Angiotensin II Antagonist Combination Treatment GUIDELINES
ACE Inhibitor and Angiotensin II Antagonist Combination Treatment Date written: September 2004 Final submission: September 2005 Author: Kathy Nicholls GUIDELINES No recommendations possible based on Level
More informationCase Presentation Turki Al-Hussain, MD
Case Presentation Turki Al-Hussain, MD Director, Renal Pathology Chapter Saudi Society of Nephrology & Transplantation Consultant Nephropathologist & Urological Pathologist Department of Pathology & Laboratory
More informationMycophenolate mofetil therapy for steroid-resistant IgA nephropathy with the nephrotic syndrome in children
Pediatr Nephrol (2015) 30:1121 1129 DOI 10.1007/s00467-014-3041-y ORIGINAL ARTICLE Mycophenolate mofetil therapy for steroid-resistant IgA nephropathy with the nephrotic syndrome in children Zhijuan Kang
More informationCorticosteroid Effectiveness in IgA Nephropathy: Long-Term Results of a Randomized, Controlled Trial
J Am Soc Nephrol 15: 157 163, 2004 Corticosteroid Effectiveness in IgA Nephropathy: Long-Term Results of a Randomized, Controlled Trial CLAUDIO POZZI,* SIMEONE ANDRULLI,* LUCIA DEL VECCHIO,* PATRIZIA MELIS,
More informationArticle. The Use of the Oxford Classification of IgA Nephropathy to Predict Renal Survival
Article The Use of the Oxford Classification of IgA Nephropathy to Predict Renal Survival Eric Alamartine,* Catherine Sauron,* Blandine Laurent, Aurore Sury,* Aline Seffert,* and Christophe Mariat* Summary
More information(renoprotective (end-stage renal disease, ESRD) therapies) (JAMA)
[1], 1., 2. 3. (renoprotective (end-stage renal disease, ESRD) therapies) (JAMA) (multiple risk (renal replacement therapy, RRT) factors intervention treatment MRFIT) [2] ( 1) % (ESRD) ( ) ( 1) 2001 (120
More informationCLINICAL PROFILE AND SHORT TERM OUT COMES IN PATIENTS OF IGA NEPHROPATHY. Victoria Hospital Campus, Republic of India, Bengaluru, India
TJPRC: International Journal of Nephrology, Renal Therapy and Renovascular Disease (TJPRC: IJNRTRD) Vol. 2, Issue 1, Jun 2018, 1-6 TJPRC Pvt. Ltd CLINICAL PROFILE AND SHORT TERM OUT COMES IN PATIENTS OF
More informationRejection or Not? Interhospital Renal Meeting 10 Oct Desmond Yap & Sydney Tang Queen Mary Hospital
Rejection or Not? Interhospital Renal Meeting 10 Oct 2007 Desmond Yap & Sydney Tang Queen Mary Hospital Case Presentation F/61 End stage renal failure due to unknown cause Received HD in private hospital
More informationSecondary IgA Nephropathy & HSP
Secondary IgA Nephropathy & HSP Anjali Gupta, MD 1/11/11 AKI sec to Hematuria? 65 cases of ARF after an episode of macroscopic hematuria have been reported in the literature in patients with GN. The main
More informationOut of date SUGGESTIONS FOR CLINICAL CARE (Suggestions are based on level III and IV evidence)
Membranous nephropathy role of cyclosporine therapy Date written: July 2005 Final submission: September 2005 Author: Merlin Thomas GUIDELINES a. The use of cyclosporine therapy alone to prevent progressive
More informationA clinical syndrome, composed mainly of:
Nephritic syndrome We will discuss: 1)Nephritic syndrome: -Acute postinfectious (poststreptococcal) GN -IgA nephropathy -Hereditary nephritis 2)Rapidly progressive GN (RPGN) A clinical syndrome, composed
More informationOriginal. IgAN. Key words : IgA nephropathy, IgM deposition, proteinuria, tonsillectomy, steroid pulse therapy. Introduction
Showa Univ J Med Sci 27 3, 167 174, September 2015 Original Prominent IgM Deposition in Glomerulus Is Associated with Severe Proteinuria and Reduced after Combined Treatment of Tonsillectomy with Steroid
More informationAtypical IgA Nephropathy
Atypical IgA Nephropathy Richard J. Glassock, MD, MACP Geffen School of Medicine at UCLA XXXIII Chilean Congress of Nephrology, Hypertension and Transplantation Puerto Varas, Chile October 6, 2016 IgA
More informationSpontaneous remission of nephrotic syndrome in patients with IgA nephropathy
Nephrol Dial Transplant (2011) 26: 1570 1575 doi: 10.1093/ndt/gfq559 Advance Access publication 14 September 2010 Spontaneous remission of nephrotic syndrome in patients with IgA nephropathy Seung Hyeok
More informationCase Presentation Turki Al-Hussain, MD
Case Presentation Turki Al-Hussain, MD Director, Renal Pathology Chapter Saudi Society of Nephrology & Transplantation Consultant Nephropathologist & Urological Pathologist Department of Pathology & Laboratory
More informationTreatment of Early Immunoglobulin A Nephropathy by Angiotensin-converting Enzyme Inhibitor
CLINICAL RESEARCH STUDY Treatment of Early Immunoglobulin A Nephropathy by Angiotensin-converting Enzyme Inhibitor Philip Kam-Tao Li, MD, Bonnie Ching-Ha Kwan, MBBS, Kai-Ming Chow, MBChB, Chi-Bon Leung,
More informationFIBRILLARY GLOMERULONEPHRITIS DIAGNOSTIC CRITERIA, PITFALLS, AND DIFFERENTIAL DIAGNOSIS
FIBRILLARY GLOMERULONEPHRITIS DIAGNOSTIC CRITERIA, PITFALLS, AND DIFFERENTIAL DIAGNOSIS Guillermo A. Herrera MD Louisiana State University, Shreveport Fibrils in bundles 10-20 nm d Diabetic fibrillosis
More informationDr Ian Roberts Oxford. Oxford Pathology Course 2010 for FRCPath Illustration-Cellular Pathology. Oxford Radcliffe NHS Trust
Dr Ian Roberts Oxford Oxford Pathology Course 2010 for FRCPath Present the basic diagnostic features of the commonest conditions causing proteinuria & haematuria Highlight diagnostic pitfalls Nephrotic
More informationRandom forest can accurately predict the development of end-stage renal disease in immunoglobulin a nephropathy patients
Original Article Page 1 of 8 Random forest can accurately predict the development of end-stage renal disease in immunoglobulin a nephropathy patients Xin Han 1#, Xiaonan Zheng 2#, Ying Wang 3, Xiaoru Sun
More informationProceedings of the 34th World Small Animal Veterinary Congress WSAVA 2009
www.ivis.org Proceedings of the 34th World Small Animal Veterinary Congress WSAVA 2009 São Paulo, Brazil - 2009 Next WSAVA Congress : Reprinted in IVIS with the permission of the Congress Organizers PROTEINURIA
More informationNephrotic Syndrome NS
Nephrotic Syndrome NS By : Dr. Iman.M. Mudawi Pediatric Nephrology Unit Gaafar Ibn Auf Hospital Definitions: In children NS is applied to any condition with a triad of: Heavy proteinuria (UACR ratio >200
More informationEffects of Two Immunosuppressive Treatment Protocols for IgA Nephropathy
Effects of Two Immunosuppressive Treatment Protocols for IgA Nephropathy Thomas Rauen, 1 Christina Fitzner, 2 Frank Eitner, 1,3 Claudia Sommerer, 4 Martin Zeier, 4 Britta Otte, 5 Ulf Panzer, 6 Harm Peters,
More informationLupus Related Kidney Diseases. Jason Cobb MD Assistant Professor Renal Division Emory University School of Medicine October 14, 2017
Lupus Related Kidney Diseases Jason Cobb MD Assistant Professor Renal Division Emory University School of Medicine October 14, 2017 Financial Disclosures MedImmune Lupus Nephritis Kidney Biopsy Biomarkers
More informationLONG-TERM OUTCOME OF PATIENTS WITH LUPUS NEPHRITIS: A SINGLE CENTER EXPERIENCE
& LONG-TERM OUTCOME OF PATIENTS WITH LUPUS NEPHRITIS: A SINGLE CENTER EXPERIENCE Senija Rašić 1 *, Amira Srna 1, Snežana Unčanin 1, Jasminka Džemidžić 1, Damir Rebić 1, Alma Muslimović 1, Maida Rakanović-Todić
More informationTreatment Aspects of Primary Nephrotic Syndrome in Adults
& Treatment Aspects of Primary Nephrotic Syndrome in Adults Senija Rašić*¹, Snježana Unčanin¹, Jasminka Džemidžić¹, Kenana Aganović¹, Amira Srna¹, Ismar Rašić² 1. Institute for Nephrology, Clinical Centre
More informationPRIMARY GLOMERULAR DISEASES
University of Sydney PRIMARY GLOMERULAR DISEASES David Harris 8/2015 Westmead Hospital KDIGO GUIDELINES Steroid-sensitive & resistant nephrotic syndrome in children Minimal-change disease and FSGS in children
More informationApproach to Glomerular Diseases: Clinical Presentation Nephrotic Syndrome Nephritis
GLOMERULONEPHRITIDES Vivette D Agati Jai Radhakrishnan Approach to Glomerular Diseases: Clinical Presentation Nephrotic Syndrome Nephritis Heavy Proteinuria Renal failure Low serum Albumin Hypertension
More informationThe most widespread type of glomerulonephritis is IgA
CJASN epress. Published on May 28, 2008 as doi: 10.2215/CJN.00310108 Effect of Tonsillectomy Plus Steroid Pulse Therapy on Clinical Remission of IgA Nephropathy: A Controlled Study Hiroyuki Komatsu, Shouichi
More informationAdministration of low-dose cyclosporine alone for the treatment of elderly patients with membranous nephropathy
Administration of low-dose cyclosporine alone for the treatment of elderly patients with membranous nephropathy M.X. Li, Y.W. Yu, Z.Y. Zhang, H.D. Zhao and F.L. Xiao Department of Nephrology, The Navy
More informationTHE KIDNEY AND SLE LUPUS NEPHRITIS
THE KIDNEY AND SLE LUPUS NEPHRITIS JACK WATERMAN DO FACOI 2013 NEPHROLOGY SIR RICHARD BRIGHT TERMINOLOGY RENAL INSUFFICIENCY CKD (CHRONIC KIDNEY DISEASE) ESRD (ENDSTAGE RENAL DISEASE) GLOMERULONEPHRITIS
More informationNon-immunosuppressive treatment for IgA nephropathy (Review)
Non-immunosuppressive treatment for IgA nephropathy (Review) Reid S, Cawthon PM, Craig JC, Samuels JA, Molony DA, Strippoli GFM This is a reprint of a Cochrane review, prepared and maintained by The Cochrane
More informationChapter 6: Idiopathic focal segmental glomerulosclerosis in adults Kidney International Supplements (2012) 2, ; doi: /kisup.2012.
http://www.kidney-international.org chapter 6 & 2012 KDIGO Chapter 6: Idiopathic focal segmental glomerulosclerosis in adults Kidney International Supplements (2012) 2, 181 185; doi:10.1038/kisup.2012.19
More informationSteroid Resistant Nephrotic Syndrome. Sanjeev Gulati, Debashish Sengupta, Raj K. Sharma, Ajay Sharma, Ramesh K. Gupta*, Uttam Singh** and Amit Gupta
Steroid Resistant Nephrotic Syndrome Sanjeev Gulati, Debashish Sengupta, Raj K. Sharma, Ajay Sharma, Ramesh K. Gupta*, Uttam Singh** and Amit Gupta From the Departments of Nephrology, Pathology* and Biostatistics**,
More informationObjectives. Pre-dialysis CKD: The Problem. Pre-dialysis CKD: The Problem. Objectives
The Role of the Primary Physician and the Nephrologist in the Management of Chronic Kidney Disease () By Brian Young, M.D. Assistant Clinical Professor of Medicine David Geffen School of Medicine at UCLA
More informationManagement and treatment of glomerular diseases KDIGO Controversies Conference Part 1
Management and treatment of glomerular diseases KDIGO Controversies Conference Part 1 Dr.M.Matinfar Assistant Professor of Internal Medicine & Nephrology IUMS -IKRC GENERAL PRINCIPLES IN THE MANAGEMENT
More informationGlomerular diseases mostly presenting with Nephritic syndrome
Glomerular diseases mostly presenting with Nephritic syndrome 1 The Nephritic Syndrome Pathogenesis: proliferation of the cells in glomeruli & leukocytic infiltrate Injured capillary walls escape of RBCs
More informationOUT OF DATE. Choice of calcineurin inhibitors in adult renal transplantation: Effects on transplant outcomes
nep_734.fm Page 88 Friday, January 26, 2007 6:47 PM Blackwell Publishing AsiaMelbourne, AustraliaNEPNephrology1320-5358 2006 The Author; Journal compilation 2006 Asian Pacific Society of Nephrology? 200712S18897MiscellaneousCalcineurin
More informationThe CARI Guidelines Caring for Australians with Renal Impairment. Specific effects of calcium channel blockers in diabetic nephropathy GUIDELINES
Specific effects of calcium channel blockers in diabetic nephropathy Date written: September 2004 Final submission: September 2005 Author: Kathy Nicholls GUIDELINES a. Non-dihydropyridine calcium channel
More informationProf. Rosanna Coppo Director of the Nephrology, Dialysis and Transplantation Department Regina Margherita Hospital Turin, Italy. Slide 1.
ROLE OF PATHOLOGY AND CLINICAL FEATURES IN PREDICTING PROGRESSION OF IGA NEPHROPATHY: RESULTS FROM THE ERA-EDTA RESEARCH VALIGA Rosanna Coppo, Turin, Italy Chairs: François Berthoux, Saint-Etienne, France
More informationClinicopathologic Correlation in IgA Nephropathy
Clinicopathologic Correlation in IgA Nephropathy David Philibert, MD, FRCPC,* Daniel Cattran, MD, FRCPC,* and Terence Cook, FRCPath Summary: IgA nephropathy is the most common biopsy-proven pattern of
More informationSpecial Challenges and Co-Morbidities
Special Challenges and Co-Morbidities Renal Disease/ Hypertension/ Diabetes in African-Americans M. Keith Rawlings, MD Medical Director Peabody Health Center AIDS Arms, Inc Dallas, TX Chair, Internal Medicine
More informationDense deposit disease with steroid pulse therapy
Case Report Dense deposit disease with steroid pulse therapy Jun Odaka, Takahiro Kanai, Takane Ito, Takashi Saito, Jun Aoyagi, and Mariko Y Momoi Abstract Treatment of dense deposit disease DDD has not
More informationRENAL HISTOPATHOLOGY
RENAL HISTOPATHOLOGY Peter McCue, M.D. Department of Pathology, Anatomy & Cell Biology Sidney Kimmel Medical College There are no conflicts of interest. 1 Goals and Objectives! Goals Provide introduction
More informationMonoclonal Gammopathies and the Kidney. Tibor Nádasdy, MD The Ohio State University, Columbus, OH
Monoclonal Gammopathies and the Kidney Tibor Nádasdy, MD The Ohio State University, Columbus, OH Monoclonal gammopathy of renal significance (MGRS) Biopsies at OSU (n=475) between 2007 and 2016 AL or AH
More informationC1q nephropathy: a true immune complex disease or an immunologic epiphenomenon?
NDT Plus (2009) 2: 285 291 doi: 10.1093/ndtplus/sfp055 Advance Access publication 9 May 2009 Case Report C1q nephropathy: a true immune complex disease or an immunologic epiphenomenon? Mordi Muorah 1,ManishD.Sinha
More informationLaunch Meeting 3 rd April 2014, Lucas House, Birmingham
Angiotensin Converting Enzyme inhibitor (ACEi) / Angiotensin Receptor Blocker (ARB) To STOP OR Not in Advanced Renal Disease Launch Meeting 3 rd April 2014, Lucas House, Birmingham Prof Sunil Bhandari
More informationShould We Use Steroids and How for Treating IgA Nephropathy?
The 25th Budapest Nephrology School Budapest 26-31 August, 2018 Nephrology, Hypertension, Dialysis, Transplantation,2 Should We Use Steroids and How for Treating IgA Nephropathy? Francesco Locatelli MD,FRCPC
More informationRENAL EVENING SPECIALTY CONFERENCE
RENAL EVENING SPECIALTY CONFERENCE Harsharan K. Singh, MD The University of North Carolina at Chapel Hill Disclosure of Relevant Financial Relationships No conflicts of interest to disclose. CLINICAL HISTORY
More informationRenal Pathology 1: Glomerulus. With many thanks to Elizabeth Angus PhD for EM photographs
Renal Pathology 1: Glomerulus With many thanks to Elizabeth Angus PhD for EM photographs Anatomy of the Kidney http://www.yalemedicalgroup.org/stw/page.asp?pageid=stw028980 The Nephron http://www.beltina.org/health-dictionary/nephron-function-kidney-definition.html
More informationAngiotensin-converting enzyme inhibitors (ACEI) and
Are Two Better Than One? Angiotensin-Converting Enzyme Inhibitors Plus Angiotensin Receptor Blockers for Reducing Blood Pressure and Proteinuria in Kidney Disease Stuart L. Linas Department of Internal
More informationRituximab treatment for fibrillary glomerulonephritis
Nephrol Dial Transplant (2014) 29: 1925 1931 doi: 10.1093/ndt/gfu189 Advance Access publication 27 May 2014 Rituximab treatment for fibrillary glomerulonephritis Jonathan Hogan, Michaela Restivo, Pietro
More informationResearch Article Transplant Outcomes in Patients with Idiopathic Membranous Nephropathy
International Nephrology Volume 2013, Article ID 818537, 4 pages http://dx.doi.org/10.1155/2013/818537 Research Article Transplant Outcomes in Patients with Idiopathic Membranous Nephropathy Claire Kennedy,
More informationRECURRENT AND DE NOVO RENAL DISEASES IN THE ALLOGRAFT. J. H. Helderman,MD,FACP,FAST
RECURRENT AND DE NOVO RENAL DISEASES IN THE ALLOGRAFT J. H. Helderman,MD,FACP,FAST Vanderbilt University Medical Center Professor of Medicine, Pathology and Immunology Medical Director, Vanderbilt Transplant
More informationIgA nephropathy in Greece: data from the registry of the Hellenic Society of Nephrology
Clinical Kidney Journal, 2018, vol. 11, no. 1, 38 45 doi: 10.1093/ckj/sfx076 Advance Access Publication Date: 31 July 2017 Original Article ORIGINAL ARTICLE IgA nephropathy in Greece: data from the registry
More informationBiopsy-Proven Childhood Glomerulonephritis in Johor
ORIGINAL ARTICLE Biopsy-Proven Childhood Glomerulonephritis in Johor J J Khoo, MPath*, S Pee, MRCP**, B Thevarajah, MRCP***, Y C Yap, MRCP**, C K Chin, MRCP**** 'Department of Pathology, "Department of
More informationProf. Armando Torres Nephrology Section Hospital Universitario de Canarias University of La Laguna Tenerife, Canary Islands, Spain.
Does RAS blockade improve outcomes after kidney transplantation? Armando Torres, La Laguna, Spain Chairs: Hans De Fijter, Leiden, The Netherlands Armando Torres, La Laguna, Spain Prof. Armando Torres Nephrology
More informationHenoch-Schoenlein Purpura / IgA Vasculitis: past and present
Henoch-Schoenlein Purpura / IgA Vasculitis: past and present S.Marinaki Nephrology Department and Renal Transplant Unit University of Athens,Laiko General Hospital Athens,Greece 4 th -8 th October 2017
More informationInternal Medicine ( ) 51 巻 11 号 :1323~1328.
Internal Medicine (2012.01) 51 巻 11 号 :1323~1328. Retrospective Comparison of the Efficacy of Tonsillectomy with and without Steroid-pulse Therapy in IgA Nephropathy Patients. Nakagawa Naoki, Kabara Maki,
More informationGlomerular pathology-2 Nephritic syndrome. Dr. Nisreen Abu Shahin
Glomerular pathology-2 Nephritic syndrome Dr. Nisreen Abu Shahin 1 The Nephritic Syndrome Pathogenesis: inflammation proliferation of the cells in glomeruli & leukocytic infiltrate Injured capillary walls
More informationXi Yang, Ri-Bao Wei, Ping Li, Yue Yang, Ting-Yu Su, Yu-Wei Gao, Qing-Ping Li, Xue-Guang Zhang, Xiang-Mei Chen
Int J Clin Exp Pathol 2016;9(9):9401-9407 www.ijcep.com /ISSN:1936-2625/IJCEP0028098 Original Article Correlation between serum hepatitis B virus DNA replication level and clinicopathology in 235 patients
More informationLupus and Your Kidneys. Michael P. Madaio, MD Professor of Medicine Chairman of Medicine Medical College of Georgia Augusta, Georgia
Lupus and Your Kidneys Michael P. Madaio, MD Professor of Medicine Chairman of Medicine Medical College of Georgia Augusta, Georgia Kidney Inflammation and Abnormal Function as a Result of Lupus (Lupus
More informationKerry Cooper M.D. Arizona Kidney Disease and Hypertension Center April 30, 2009
Kerry Cooper M.D. Arizona Kidney Disease and Hypertension Center April 30, 2009 DR. KERRY COOPER IS ON THE SPEAKER BUREAU OF AMGEN, ABBOTT, GENZYME, SHIRE, AND BMS DR. COOPER IS ALSO INVOLVED IN CLINICAL
More informationRenal manifestations of IgG4-related systemic disease
Renal manifestations of IgG4-related systemic disease Lynn D. Cornell, M.D. Mayo Clinic Rochester, MN While autoimmune pancreatitis (AIP) has been recognized since the first description by Sarles et al
More informationChronic Kidney Disease. Paul Cockwell Queen Elizabeth Hospital Birmingham
Chronic Kidney Disease Paul Cockwell Queen Elizabeth Hospital Birmingham Paradigms for chronic disease 1. Acute and chronic disease is closely linked 2. Stratify risk and tailor interventions around failure
More informationPathology of Complement Mediated Renal Disease
Pathology of Complement Mediated Renal Disease Mariam Priya Alexander, MD Associate Professor of Pathology GN Symposium Hong Kong Society of Nephrology July 8 th, 2017 2017 MFMER slide-1 The complement
More informationYear 2004 Paper one: Questions supplied by Megan
QUESTION 53 Endothelial cell pathology on renal biopsy is most characteristic of which one of the following diagnoses? A. Pre-eclampsia B. Haemolytic uraemic syndrome C. Lupus nephritis D. Immunoglobulin
More informationGOODPASTURE'S SYNDROME WITH CONCOMITANT IMMUNE COMPLEX MIXED MEMBRANOUS AND PROLIFERATIVE GLOMERULONEFRITIS
GOODPASTURE'S SYNDROME WITH CONCOMITANT IMMUNE COMPLEX MIXED MEMBRANOUS AND PROLIFERATIVE GLOMERULONEFRITIS VESNA JURČIĆ 1, ANDREJA ALEŠ RIGLER 2, INSTITUTE OF PATHOLOGY, FACULTY OF MEDICINE, UNIVERSITY
More informationGlomerulonephritis: Evidence Based Management
CHAPTER 11 Glomerulonephritis: Evidence Based Management R. A. Annigeri Introduction Glomerulonephritis is the second most common cause of end-stage renal disease (ESRD) worldwide, next only to diabetic
More informationValidation of the Oxford Classification of IgA Nephropathy: A Single-Center Study in Korean Adults
original article korean j intern med 202;27:293-300 pissn 226-3303 eissn 2005-6648 Validation of the Oxford Classification of IgA Nephropathy: A Single-Center Study in Korean Adults Hoyoung Lee, Sul Hee
More informationDr. Ghadeer Mokhtar Consultant pathologists and nephropathologist, KAU
Dr. Ghadeer Mokhtar Consultant pathologists and nephropathologist, KAU CLINICAL HISTORY A 4 year old Saudi girl presented to the ER with generalized body swelling, decrease urine output with passing dark
More informationManagement and Outcome of Steroid-Resistant Nephrotic Syndrome in Children
kidney diseases Management and Outcome of Steroid-Resistant Nephrotic Syndrome in Children Hasan Otukesh, 1 Salman Otukesh, 2 Mona Mojtahedzadeh, 2 Rozita Hoseini, 1 Seyed-Mohammad Fereshtehnejad, 2 Azam
More information